Adding Trulicity to SGLT2 inhibitors lowers blood sugar levels, shows AWARD-10 data

26 February 2018

Type 2 diabetes patients whose blood sugar levels were not adequately controlled on SGLT-2 inhibitor therapy and metformin showed an improvement in average blood sugar concentration over two to three months (A1C) when Eli Lilly's (NYSE: LLY) Trulicity (dulaglutide) was added in a Phase IIIb study.

New data from the AWARD-10 study reflects that the addition of Trulicity brought a clinically meaningful and statistically significant improvement in A1C at both doses that were studied.

A statement provided by Lilly on this data read: "These results are positive for Trulicity, as they provide new information that Trulicity in combination with an SGLT-2 inhibitor may be effective and well tolerated in people with type 2 diabetes. They also show that Trulicity works effectively with all approved SGLT-2 inhibitors, as the study tested Trulicity in combination with all three available SGLT-2 inhibitors."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK